CovalX is pleased to announce the expansion of our Immunoprecipitation-Mass Spectrometry (IP-MS) services with cross-link MS (XL-MS), strengthening our ability to support drug target and protein interaction characterization across biotherapeutic discovery and development. This expansion reflects our clients’ growing demand for robust, biologically relevant methods capable of resolving molecular interactions that are often inaccessible using traditional analytical techniques. Using the combined expertise of CovalX in the field of XL-MS and IP-MS, the analysis of protein interactions in complex biological matrices becomes more sensitive, enabling the detection of low-abundance interactions.
By including established protocols for cross-link chemistry, cell lysates, magnetic bead pull-down, and protein enrichment/isolation, we can offer a more thorough analysis of protein interactions.
This powerful technique supports key applications in therapeutic development, including target identification, biomarker validation, and deeper insight into the mechanism of action for drug candidates. This allows scientists to confirm interactions that are pivotal for downstream decision-making in preclinical research.
CovalX’s IP-MS workflows highlight analytical specificity, reproducibility, and data quality. These insights help de-risk discovery programs by confirming target engagement and clarifying biological relevance early in development.